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production and a greater degree of inflammation,
and favour the penetration of antibiotics into
the gastric mucosa; bacterial genetic traits may
therefore be linked not only to gastric histo-
pathology, but also to the success of antibiotic
treatment.
In conclusion, multiparametric studies are
required to better define the heterogeneous nature
of H. pylori strains colonising humans. A com-
bined approach, including the correlation
between in-vitro antibiotic testing, in-vivo treat-
ment outcome, and bacterial genotypic traits, may
improve our knowledge significantly.
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Antimicrobial resistance of Acinetobacter
spp. in Europe
We congratulate Drs Van Looveren and Goossens
for their excellent review regarding the antimi-
crobial resistance of Acinetobacter spp. in Europe
[1]. We agree with their statement that colistin
should be considered as a therapeutic option in
patients with severe infections caused by multi-
drug-resistant Acinetobacter baumannii strains.
However, we believe that results from recent
studies suggest that colistin is less toxic than
thought previously and reported in the review. In
fact, the reported rates of nephrotoxicity (27%
and 58% in patients with baseline normal and
abnormal renal function, respectively) do not
represent development of ‘renal failure’, as stated
in the review [1] and the original paper by Levin
et al. [2], but rather renal dysfunction, as evi-
denced by only a moderate increase in serum
creatinine levels. Specifically, it is stated in the
original paper [2] that the mean (± SD) increase in
serum creatinine concentration was 0.9 ±
0.6 mg ⁄dL in patients with normal baseline cre-
atinine levels, and 1.5 ± 1.4 mg ⁄dL in patients
with abnormal baseline creatinine levels. In addi-
tion, nephrotoxicity did not lead to discontinu-
ation of treatment for any of the patients in that
study, and was reversible in a considerable
proportion of patients. Other investigators, inclu-
ding our own group [3,4], have noted that the use
of intravenous colistin is associated with consid-
erably less nephrotoxicity than reported previ-
ously. In addition, Garnacho-Montero et al. [5]
reported an almost two-fold nephrotoxicity rate
among patients treated for A. baumannii ventila-
tor-associated pneumonia with imipenem when
compared to colistin-treated patients [5].
Another point of interest is that methods of
colistin administration other than the intravenous
route may have clinical value. These include
aerosolised (nebulised) administration of the anti-
biotic to patients with severe nosocomial pneu-
monia. The value of aerosolised colistin in the
prevention and treatment of infections caused by
Pseudomonas aeruginosa strains has already been
proven for patients with cystic fibrosis. In addi-
tion, intraventricular administration of colistin
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may prove to be a life-saving intervention for
patients with A. baumannii meningitis who do not
respond to intravenous treatment with antimicro-
bial agents, including colistin, as has been dem-
onstrated for a patient of our own [6] and a
patient from Spain [7].
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